加载中
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
NASDAQHealthcareMedical - Pharmaceuticals
最新数据
US$3.155
−US$1.725 · -35.35%
常规交易时段
US$3.155
−US$1.725 · -35.35%
盘中时间采用ET。市场数据可能有所延迟。
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
日内区间
当前US$3.155
52周区间
当前US$3.155
盘中时间采用ET。市场数据可能有所延迟。
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
日内区间
当前US$3.155
52周区间
当前US$3.155
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
